ライフサイエンスコーパス: specific drug

1 AT2 that can be utilized for making an ACAT2-specific drug.

2 eatment response in individual patients to a specific drug.

3 atic fibroblast cells treated with an asthma-specific drug.

4 ion pressures arising from population use of specific drugs.

5 rds finding effective and safe kinetoplastid-specific drugs.

6 mising possibilities for the design of VEGFR-specific drugs.

7 uiescence and hence resistance to cell-cycle specific drugs.

8 heumatic syndromes have been associated with specific drugs.

9 e C-linker/CNBHD and may guide the design of specific drugs.

10 ding cleft residues influence recognition of specific drugs.

11 osis demonstrates the need for additional TB-specific drugs.

12 n cellular water permeability and screen AQP-specific drugs.

13 e structure-based methods to design receptor-specific drugs.

14 ide synthesis, and to screen for eubacterial-specific drugs.

15 al PKC inhibitors but not by the classic PKC-specific drugs.

16 altered in human HCC that may be targeted by specific drugs.

17 (Kr)), tissue (oocytes versus myocytes), or specific drugs.

18 nt of carbohydrate based vaccines and target specific drugs.

19 , and their relationship with endorsement of specific drugs.

20 ly been associated with adverse reactions to specific drugs.

21 unding is not associated with endorsement of specific drugs.

22 cells to open the prospect of developing IN-specific drugs.

23 effects produced by currently used anti-VEGF-specific drugs.

24 nhibition of HSP90 function using the highly specific drugs 17-AAG, SNX-5422, or NVP-AUY922 reduced T

25 Part of the effort to develop hepatitis C-specific drugs a nd vaccines is the study of genetic var

26 tosoma japonicum The reason for this species-specific drug action has remained a mystery for decades.

27 Compartment-specific drug action was indeed observed.

28 sts, may hold potential for the treatment of specific drug addictions and psychiatric comorbidity.

29 ent information for the design of a safe and specific drug against T. brucei.

30 mately for structure-based design of subtype specific drugs against the nAChR associated diseases.

31 rived pK(a) values allows us to identify the specific drug amino groups whose protonation is linked t

32 Prevalence of specific drugs among decedents and proportion that had b

33 istration's approval of the first complement-specific drug, an antibody against complement component

34 Applications in the fields of sensors, site-specific drug and gene delivery or protein stabilization

35 transporters, including the proximal tubule-specific drug and organic anion transporters (OATs) OAT1

36 ese data form the basis for rational, target-specific drug and vaccination therapies currently employ

37 nimum number of intravitreal injections of a specific drug and visual acuity interval.

38 out improving medication use and withdrawing specific drugs and drug classes.

39 essary to examine drug-food interactions for specific drugs and drug formulations, additional avenues

40 Early detection may enable development of specific drugs and early initiation of therapy, thereby

41 al setting for the development of metastasis-specific drugs and for patient stratification to optimiz

42 no clear associations have been made between specific drugs and HIV lipohypertrophy, stavudine and zi

43 ASM-specific drugs and multiple small interfering RNAs stron

44 ave been assigned through serotonin-receptor-specific drugs and mutants; however, because a constella

45 flush, combining hypothermia with mechanism-specific drugs and novel fluids; b) extension of suspend

46 ent effects in their responses to two A-site-specific drugs and on suppression nonsense codons.

47 Two non-specific drugs and one non-specific aptamer, tested as s

48 -1 drug resistance selection associated with specific drugs and regimens and the consequent activity

49 tensive published data sources and considers specific drugs and resistance mutations.

50 y open new approaches for the development of specific drugs and vaccines against trypanosomiasis.

51 ill allow the rational design of schistosome-specific drugs and vaccines.

52 No specific drugs are currently available against hepatitis

53 No approved vaccines or parasite-specific drugs are currently available for the control o

54 y against all four circulating serotypes nor specific drugs are currently available to treat this eme

55 ingestion and therapeutic effects of highly specific drugs are measurable on the basis of cell elect

56 responses of different cell-based assays to specific drugs are retained when three assays are co-pla

57 In this overview, we discuss specific drug-associated hemostatic complications, the a

58 achieved by modifying stem cells to release specific drugs at the site of transplantation.

59 onal adaptability of protein kinases towards specific drug binding.

60 ivity, thus a structural description of poly-specific drug-binding is important for the rational desi

61 also reveals a novel conformation for the K5-specific drug-binding loop 5, suggesting a possible role

62 less lethal than lesions by an unrelated AT-specific drug, bizelesin.

63 es were moderate and generally similar among specific drugs, but larger among older antidepressants,

64 on of MCJ expression increases resistance to specific drugs by inducing expression of the ABCB1 drug

65 phase dynamics after exposure to the S phase specific drug, camptothecin.

66 ing, air pollution, infection, hormones, and specific drugs can contribute to this phenotype, other f

67 ts point to the necessity of developing site-specific drug carriers to improve the delivery of molecu

68 ence of comorbid conditions often determines specific drug choices.

69 An AE-specific drug class effect is defined to exist when all

70 nes and/or consensus documents on general or specific drug class-induced DHRs are available to suppor

71 Specific drug classes associated with otherwise unexplai

72 Increased cell viability and resistance to specific drug classes in the BM stroma-derived condition

73 The purported superiority of specific drug classes, notably angiotensin-converting en

74 In recent years, more specific drugs, collectively known as biologics, have be

75 ivities may be therapeutically targeted with specific drug combinations.

76 It has been possible to recommend specific drug concentration for betalactam antibiotics,

77 hip with a mixing network is used to achieve specific drug concentrations for drug titration experime

78 The results demonstrate that the site-specific drug conjugation at the engineered Cys residue

79 h regard to therapeutic implications, NOTCH3-specific drugs could represent a valuable strategy to li

80 diverse human genetic backgrounds respond to specific drugs, creating the possibility of personalized

81 iased from fitting the structural content of specific drug databases to prediction models.

82 s for development of safer vesicles for site-specific drug delivery and controlled release at patholo

83 of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parente

84 might also be a promising platform for tumor-specific drug delivery and other Hsp70-based targeted th

85 Externally controlled site specific drug delivery could potentially provide a means

86 nds that could serve as directive agents for specific drug delivery in hematologic malignancies.

87 However, effective ATII cell-specific drug delivery in vivo requires carriers of an a

88 Additionally, specific drug delivery issues, duration of therapy, init

89 o treat and when in their course of disease, specific drug delivery issues, duration of therapy, mana

90 e also discussed various techniques for site-specific drug delivery of anti-PAH therapeutics so as to

91 of using these sequences to construct joint-specific drug delivery systems that may have considerabl

92 operties with applications ranging from site-specific drug delivery to anodes for lithium-ion batteri

93 s study demonstrates the feasibility of site-specific drug delivery to implanted magnetizable stents

94 in provides an effective approach for tissue-specific drug delivery to the bone marrow.

95 effective means of providing sustained, site-specific drug delivery to the porcine coronary artery wa

96 and RAFT have significant potential for site-specific drug delivery to tissues with high levels of ox

97 vidual patient followed by optimized, target-specific drug delivery, may potentially improve efficacy

98 ide localization could be leveraged for site-specific drug delivery, while the decreased propensity o

99 l configurations of nanocarriers for disease-specific drug delivery.

100 here are limitations to their use for target specific drug delivery.

101 ique for non-invasive gene therapy and organ-specific drug delivery.

102 yte that leads to a triggering mechanism for specific drug delivery.

103 nostructure carrying a high drug payload for specific drug delivery.

104 by the nanochain facilitates widespread site-specific drug delivery.

105 vestigated for multimodal imaging and target specific drug delivery.

106 ely has led to intense investigation of site-specific drug-delivery systems.

107 sh whether this approach can mediate cardiac-specific, drug-dependent excision between loxP sites in

108 In fact, specific drug design theories depend upon this assumptio

109 ich could direct GlyR beta+/alpha- interface-specific drug design, but also provides a general method

110 of scleritis offers hope for future molecule-specific drug design.

111 lidate these residues as targets for species-specific drug design.

112 and can be an attractive target for pathway-specific drug design.

113 For specific drug development and to study distinct arrhythm

114 PAK3 may thus represent such targets for p53-specific drug development.

115 the possibilities and challenges of pathway-specific drug development.

116 ue engineering, joint surgery, and cartilage-specific drug development.

117 oach is an effective and robust tool for MCU-specific drug discovery and, more generally, for the ide

118 ide theoretical targets for tumor suppressor-specific drug discovery efforts.

119 sents a new class of PDE-based complexes for specific drug discovery targeting the cAMP signaling pat

120 ttern-learning approach to extract treatment-specific drug-disease pairs from 20 million biomedical a

121 rendered it sensitive to the otherwise mouse-specific drug DMXAA, a conclusion validated by binding s

122 notyping may be of value in planning patient-specific drug dosing.

123 alogues (octreotide) has replaced older less specific drugs (e.g. antihistamines) for the treatment o

124 ntitatively and simultaneously measure stage-specific drug effects on parasites at different developm

125 ls, yielding a restoration of ABCG2-mediated specific drug efflux activity.

126 ing clinical response to treatment with four specific drugs: etanercept, ustekinumab, adalimumab, and

127 quantify the signals of sex differences for specific drug-event combinations.

128 Together, the data suggest that specific drug-FABP complexes can interact with PPARalpha

129 cacies is critical in designing functionally specific drugs for GPCRs.

130 k in the skin could offer the development of specific drugs for novel treatment modalities.

131 ther excitable cells, there are virtually no specific drugs for this K+ channel.

132 ghts will facilitate the development of P2X7-specific drugs for treating human diseases.

133 The resulting specific drug formulation agents render insoluble drugs

134 tion of the Hsp90.PAR-1 complex by the Hsp90-specific drug geldanamycin attenuated thrombin-mediated

135 glycosylation has led to the development of specific drug glycoforms, for example, monoclonal antibo

136 also enhanced their sensitivity to the Ezh2-specific drug, GSK126 through increased growth inhibitio

137 No specific drug has been shown to prevent radiation-induce

138 Cell-based screening for novel tumor-specific drugs has been compromised by the lack of appro

139 Although several target-specific drugs have altered the paradigm of treatment fo

140 sistent with any serious lung disease, as no specific drugs have been approved as therapeutics.

141 Although VGSC beta subunit-specific drugs have not yet been developed, this protein

142 gs support the possible application of TORC2-specific drugs in cancer therapy.

143 se of manuscript writers, and endorsement of specific drugs in the abstract of the article.

144 The specific drug-induced electrolyte disorders discussed in

145 structural and functional bases of anti-VEGF-specific drug-induced side effects in relation to vascul

146 FVT sites received PDT according to specific drug infusion and laser light treatment paramet

147 Minor groove-specific drugs inhibit TIF-IB binding, with higher conce

148 An allele-specific drug inhibiting the essential gene remaining in

149 um and Src family kinase dependent by use of specific drug inhibitors and dominant negative kinase tr

150 e molecules in HNSCC and their inhibition by specific drug interaction; the relevance of these probes

151 r model can be a useful tool to study tissue-specific drug interactions and the effects of disease-re

152 d photoaffinity analog and used to probe for specific drug interactions with the HA protein.

153 With the aid of specific drug intermediates and APIs, we chart the devel

154 Of specific drugs investigated, atazanavir, atazanavir/rito

155 termine the permeability coefficient for the specific drug-lipid system.

156 studies have focused on interactions between specific drugs, little is known about the system propert

157 toid arthritis and developments of new, more specific drugs may be of particular benefit to patients

158 s obtained in a library screen, and to score specific drug-mediated disruption of protein-protein int

159 Alterations in electrolyte balance and organ-specific drug metabolism may contribute to complications

160 ect their blood levels, and the individual's specific drug-metabolizing enzyme profile may contribute

161 ovo design of telodendrimer nanocarriers for specific drug molecules, which is a promising approach t

162 fection in the presence of cocaine (Coc) and specific drugs namely i.e., tenofovir (Tef), rimcazole (

163 We therefore tested the effect of pathway-specific drugs on endurance capacities of mice in a trea

164 understanding of the mechanisms of action of specific drugs on the atrial substrate at different stag

165 ion, insights into the biological effects of specific drugs on transplanted cells are critical in ide

166 No approved specific drugs or vaccinations are available to treat th

167 in PAH therapeutics with an emphasis on site-specific drug payload delivery.

168 receptor critical for determining whether a specific drug pharmacophore triggers receptor activation

169 rk analysis, and ultimately predicts disease-specific drug polypharmacology through systems-based gen

170 Specific drug-protein interactions validate an allosteri

171 edback including alerts, reminders, and unit-specific drug rate limits.

172 rmine binding sites, bound conformations and specific drug-receptor interactions for several alloster

173 ationalize the mechanism of promiscuous, yet specific, drug recognition: (i) a four-ring motif presen

174 ervices, infant feeding recommendations, and specific drug regimens necessary to achieve this goal in

175 The specific drug release can be achieved through a careful

176 or light have been developed to trigger site-specific drug release.

177 Cell cycle phase-specific drug resistance is an escape mechanism of melan

178 e household MDR strains were analyzed for 10 specific drug resistance-associated polymorphisms previo

179 ass 1 ALDH alone is sufficient to confer OAP-specific drug resistance.

180 ment of latent infection according to region-specific drug-resistance profiles could improve the effi

181 Region-specific drug-resistance profiles were derived from data

182 tinguish between generic stress response and specific drug response.

183 Although patient-specific drug responses are common, for many patients, c

184 a provide evidence for CRC proteomic subtype-specific drug responses.

185 Treatment with various cytoskeleton-specific drugs revealed that the intact actomyosin motil

186 o two classes: (1) those that interfere with specific drug-ribosome interactions and (2) those that s

187 llicit drug overdose deaths but obscures the specific drug(s) involved.

188 sed in vitro to predict and validate patient-specific drug safety and efficacy, potentially enabling

189 or resistant clones were detected with clone-specific drug screening.

190 or FCOIs are prevalent, and endorsement of a specific drug seems to be more common when authors have

191 may serve to link the molecular defects with specific drug sensitivities.

192 domains were functional and exhibited family-specific drug sensitivity.

193 slation and hypersensitivity toward the eEF2-specific drug sordarin).

194 er cells and targets for extremely lethal AT-specific drugs, such as bizelesin.

195 that accumulation of metabolites involved in specific drug target activity was linked to the buildup

196 er HTS of greater than 10(6) compounds for a specific drug target conclusively demonstrates a new app

197 n of its biosynthesis may provide a parasite-specific drug target.

198 , with a few exceptions, the disease lacks a specific drug target.

199 d thus may represent an example of a species-specific drug target.

200 data identify mutp53 as an actionable cancer-specific drug target.

201 es, thereby offering a potential and species-specific drug target.

202 bacterial surface, which alter the nature of specific drug-target interactions.

203 Organ specific drug targeting was explored in mice as a possib

204 n of the peptides as vehicles for hepatocyte-specific drug targeting.

205 rs and provide a template for designing more specific drugs targeting the folate receptor system.

206 y prove useful in identifying and validating specific drug targets and in deconvolving the effects of

207 the brain parenchyma, and the need for tumor-specific drug targets and pharmacologic agents to inhibi

208 trol APP expression and provide suitable and specific drug targets for AD.

209 cept in AF pathogenesis and may provide more specific drug targets for treating AF.

210 ation of tumor character and suggest subtype-specific drug targets.

211 ical roles of senescent cells and developing specific drug targets.

212 apped opportunities to discover new parasite-specific drug targets.

213 teractions between its driving mutations and specific drug targets.

214 egionally clustered samples are enriched for specific drug targets.

215 rs and present a unique platform for patient-specific drug testing.

216 effects but also correctly classify species-specific drug (Thalidomide) and false negative drug (D-p

217 and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.

218 s makes the development of more potent, more specific drugs that behave like azacitidine imperative.

219 This work may lead to the design of specific drugs that can interrupt UL37 interactions with

220 ed as an in vivo screening tool for genotype-specific drugs that enhance the effect of radiation ther

221 ble to build a safer generation of PPARgamma-specific drugs that evoke fewer side effects while prese

222 of the complex will facilitate the design of specific drugs that interfere with the S100A4-NMIIA inte

223 Thus, it may be possible to create myosin VI-specific drugs that rescue the function of deafness-caus

224 omeostasis and will allow the development of specific drugs that stimulate or inhibit these pathways.

225 The development of specific drugs that target one or more of these PLA2 enz

226 es are important for developing functionally specific drugs that will stabilize a particular receptor

227 Frequently cited reasons for this absence of specific drug therapies include the heterogeneity of pat

228 echanisms, and potentially to tailor patient-specific drug therapy.

229 lesion coverage and delivering local, lesion-specific drug therapy.

230 trategy to safely induce drug tolerance to a specific drug to limit the possibility of a type I react

231 The lack of vaccines or specific drugs to prevent or treat HFRS and HCPS and the

232 There are no vaccines or specific drugs to prevent or treat HPS, and the pathogen

233 This information may help in the design of specific drugs to prevent this condition.

234 , in combination therapies with other cancer-specific drugs, to maximize tumor cell killing while pro

235 e confirmed by analyzing isolated samples of specific drug-to-antibody ratio species.

236 e is truly localised in the context of organ-specific drug toxicity.

237 No specific drug treatment exists for MERS and infection pr

238 mportant insight into the dynamics between a specific drug treatment, its impact on the extent and th

239 acute pancreatitis (AP), a condition without specific drug treatment.

240 t data on protease mutations associated with specific drug treatments and mutations with positive rep

241 The role of specific drug treatments in the etiology of solid cancer

242 ls was determined by assaying the effects of specific drug treatments on the level of virus entry as

243 lution likely has been influenced by country-specific drug use regimens.

244 skeletal muscle coincident with exposure to specific drugs used during anethesia has been recognized

245 t, but that the effects are dependent on the specific drugs used during pregnancy.

246 ticipants did not express concerns about the specific drugs used for IPTc or about providing tablets

247 cohorts may be more successful than mediator-specific drugs used indiscriminately.

248 ansplant short-term results, and the lack of specific "drugs" used for this disease.

249 The absence of approved parasite-specific drugs, vaccines, and immunotherapies for crypto

250 No approved parasite-specific drugs, vaccines, or immunotherapies for control

251 used a simple binary contrast (exposure to a specific drug vs no exposure), which has potentially ser

252 d that precisely the same concentration of a specific drug was required to inhibit protein synthesis

253 No specific drug was significantly associated with remissio

254 Endorsement of specific drugs was significantly associated with author

255 RT inhibitors (NNRTIs) are a class of highly specific drugs which bind to a pocket approximately 10 A

256 ic chemical leads for the development of RTK-specific drugs with broad application for the treatment

257 tural similarity to the topoisomerase IIbeta-specific drug XK469, CQS was tested and found to be both